Articles related to MEDICAL BREAKTHROUGHS

The development of new androgen receptor pathway inhibitors (ARPis) has resulted in a dramatic therapeutic paradigm change for the older adult illness of prostate cancer. Enzalutamide is one of the ARPis that is used more frequently. Darolutamide, apalutamide, and this medication were all first approved for the treatment of metastatic castrate-resistant prostate cancer, but they are now routinely used in the treatment of metastatic castrate-sensitive and non-metastatic castration-resistant prostate cancer. Only older persons with outstanding performance status are included in landmark phase III data demonstrating the effectiveness of ARPi in these patients. However, in the context of a narrative review, its function in older prostate cancer patients who are ineligible has to be investigated.

Researchers studying acute myeloid leukemia (AML) have been able to better characterize the disease, improve risk-stratification methods, and create new treatments thanks to the era of genomic medicine. Despite major advancements, AML’s extremely intricate and plastic cellular architecture means that it is still a fatal malignancy. Because it makes it difficult to pinpoint and then eliminate the cells that cause leukemogenesis and therapy failure, this level of heterogeneity continues to be a significant obstacle. Single-cell genomics has made unheard-of advancements in the study of cellular heterogeneity in recent years, and it shows promise for the investigation of AML.

The “super enhancer,” a complex region of DNA with a lot of transcriptional machinery that determines whether a cell is malignant, can be programmed by the environment around a colon cancer tumor for the first time, according to research. The PDZK1IP1 gene, which was not previously recognized as a cancer gene, is controlled by this super enhancer, which is the biggest 1-2% of all enhancers in the cell. Colon cancer growth was inhibited when PDZK1IP1 was deleted, indicating that PDZK1IP1 and its super enhancer may be targets for cancer treatments.

The researchers put a theory to the test by administering the compound CBL0137 to melanoma mouse models. This compound causes the same type of highly inflammatory cell death that the influenza virus causes, but it does so directly in cancerous tissue. The resulting antiviral response alerted the immune system. It heated up a “cold” tumor so that, when combined with immunotherapy, the host immune system recognized cancer as something to be destroyed.

Researchers have identified a small molecule, named as SHP656, that can target the brain’s clock proteins and may prove effective for treating glioblastoma.

On September 20, 2022, Alzheon Inc. announced promising results from its phase 2 trial of oral ALZ-801 (valiltramiprosate) in patients with early AD. The drug decreased p-tau181 levels, reduced brain atrophy, and improved cognitive skills in the trial.